Status:
COMPLETED
Impact of Hybrid Coronary Revascularization on Antiplatelet Therapy
Lead Sponsor:
Aarhus University Hospital Skejby
Collaborating Sponsors:
Danish Heart Foundation
Aase and Ejnar Danielsens Foundation
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Brief Summary
The effect of antiplatelet therapy is impaired among patients, who recently underwent on-pump coronary artery bypass grafting. The impact of hybrid coronary revascularization using minimal invasive su...
Detailed Description
Objective: The effect of antiplatelet therapy is impaired among patients, who recently underwent on-pump coronary artery bypass grafting. The impact of hybrid coronary revascularization using minimal...
Eligibility Criteria
Inclusion
- symptomatic multivessel coronary artery disease
- treatment with non-enteric coated aspirin 75 mg once daily
Exclusion
- aspirin or clopidogrel intolerance
- conditions prohibitive of aspirin discontinuation prior to surgery
- use of anticoagulants or any drugs other than aspirin known to affect platelet function
- use of immunosuppressive drugs
- platelet count \<100 or \>450 x 109/l
- inability to give informed consent
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT02293928
Start Date
October 1 2010
End Date
April 1 2013
Last Update
November 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aarhus University Hospital
Aarhus, Denmark, 8200